Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
03/03/2026 13:12
March 3 (Reuters) - Transcode Therapeutics Inc RNAZ.O: TRANSCODE THERAPEUTICS INC - ENTERS EXCLUSIVE LICENSE AGREEMENT WITH UNLEASH TRANSCODE THERAPEUTICS INC - UNDER AGREEMENT, UNLEASH TO RECEIVE 1,136,364 SHARES OF TRANSCODE PREFERRED STOCK Source text: ID:nPn6tQlTva Further company coverage: RNAZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors